First Tracks Biotherapeutics, Inc.
Research First Tracks Biotherapeutics, Inc. (TRAX) on Bullrun: market cap USD 1.22B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerTRAX
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 1.22B
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 33.37M
- Free cash flow-USD 31.94M
Valuation Snapshot
latest market cap is USD 1.22B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2024 | USD 0 | -USD 163.71M | -USD 126.16M | n/a | n/a | USD 123.08M | USD 16.04M | USD 391.60M |
| FY2023 | USD 0 | -USD 106.15M | -USD 93.81M | n/a | -3.05 | USD 35.97M | USD 17.81M | USD 409.85M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-16 | USD 1.22B | n/a | n/a | n/a |
About First Tracks Biotherapeutics, Inc.
First Tracks Biotherapeutics, Inc. operates a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases in United States. Its products includes ANB033, a novel anti-CD122 antagonist that targets the shared beta subunit of the IL-15 and IL-2 receptors; Rosnilimab, a antibody engineered to selectively deplete pathogenic T cells in both the periphery and inflamed tissues;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is First Tracks Biotherapeutics, Inc.'s market cap?
First Tracks Biotherapeutics, Inc.'s market capitalization is USD 1.22B.
What does First Tracks Biotherapeutics, Inc. do?
First Tracks Biotherapeutics, Inc. operates a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases in United States. Its products includes ANB033, a novel anti-CD122 antagonist that targets the shared beta subunit of the IL-15 and IL-2 receptors; Rosnilimab, a antibody engineered to selectively deplete pathogenic T cells in both the periphery and inflamed tissues; and ANB101, a BDCA2-modulating antibody designed to specifically target plasmacytoid dendritic cells (pDCs). First Tracks Biotherapeutics, Inc.